Core Viewpoint - Concentrix Corporation has announced a public offering of $600 million in Senior Notes with a 6.500% interest rate, due in 2029, to refinance existing debt and cover related expenses [1]. Group 1: Offering Details - The offering consists of $600 million aggregate principal amount of 6.500% Senior Notes due 2029 [1]. - The proceeds will be used to redeem or repay all or a portion of the 6.650% Senior Notes due August 2, 2026, which currently has an outstanding amount of $800 million [1]. - The expected closing date for the offering is February 24, 2026, pending customary closing conditions [1]. Group 2: Management and Underwriters - The offering is managed by BofA Securities, J.P. Morgan, BNP Paribas, Citigroup, HSBC, PNC, TD Securities, Truist, U.S. Bancorp, and Wells Fargo as joint book-running managers [2]. - Co-managers for the offering include Fifth Third Securities, Goldman Sachs, MUFG Securities, and Standard Chartered Bank [2]. Group 3: Regulatory Information - The offering will be made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3]. - Investors are encouraged to read the prospectus supplement and accompanying prospectus for detailed information regarding the offering [3].

Core Insights - BioCryst Pharmaceuticals has completed the acquisition of Astria Therapeutics, enhancing its leadership in hereditary angioedema (HAE) and supporting long-term growth [1][5] Acquisition Details - The acquisition was valued at approximately $700 million, financed through cash on hand and a financing facility, with BioCryst issuing about 37.3 million shares to Astria's equity holders [5] Product Portfolio Enhancement - BioCryst adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development, which could be the first HAE therapy with every-three and every-six month dosing, improving patient treatment experiences [2][3] - The company now offers both the leading oral therapy (ORLADEYO®) and a potentially best-in-class injectable option, providing optimal choices for individualized patient care [3] Strategic Leadership Changes - Jill C. Milne, Ph.D., co-founder and CEO of Astria, has joined BioCryst's Board of Directors, while John Ruesch has been appointed as Chief Technical Operations Officer, bringing expertise in product development [6] Additional Programs - BioCryst has acquired Astria's early-stage program for atopic dermatitis, STAR0310, and plans to explore strategic alternatives for this program [4]

Core Viewpoint - QXO, Inc. has announced a public offering of 31,645,570 shares of its common stock at a price of $23.80 per share, with the offering expected to close on January 20, 2026, subject to customary closing conditions [1][2]. Group 1: Offering Details - The underwriter has an option to purchase an additional 4,746,835 shares at the public offering price, less underwriting discounts and commissions [2]. - The net proceeds from the offering will be used for general corporate purposes, which may include funding future acquisitions [2]. - BofA Securities is acting as the sole underwriter for the offering [2]. Group 2: Company Overview - QXO is the largest publicly traded distributor of roofing, waterproofing, and complementary building products in North America [5]. - The company aims to become the tech-enabled leader in the $800 billion building products distribution industry and targets $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth [5]. Group 3: Regulatory Information - The offering is being made by means of a prospectus supplement under QXO's effective registration statement on Form S-3ASR, as filed with the Securities and Exchange Commission (SEC) [3].

Core Insights - Freddie Mac sold 25 deeply delinquent non-performing residential first lien loans (NPLs) to Revolve Capital LLC for approximately $4.9 million as part of its Extended Timeline Pool Offering (EXPO) [1][2] - The transaction is expected to settle in December 2025, with marketing efforts beginning on September 25, 2025 [1] Group 1: Loan Details - The loans have an average delinquency of 22 months and an average loan balance of $196,000 [3] - Approximately 42% of the aggregate pool balance consists of previously modified mortgages that became delinquent [2] - The unpaid principal balance (UPB) weighted combined loan-to-value (CLTV) is 56%, while the broker price opinion (BPO) weighted CLTV is 50% [3] Group 2: Transaction Context - Freddie Mac's seasoned loan offerings aim to reduce less-liquid assets in its mortgage-related investments portfolio [4] - Since 2011, Freddie Mac has sold $10.7 billion of NPLs and securitized approximately $81.7 billion of re-performing loans (RPLs) [4] - The servicing requirements for these transactions focus on improving borrower outcomes and stabilizing communities [4]

Core Viewpoint - Freddie Mac has announced the pricing of the Seasoned Loans Structured Transaction Trust (SLST) Series 2025-2, which involves a securitization of approximately $343.2 million backed by seasoned residential mortgage loans [1][2]. Group 1: Transaction Details - The transaction comprises approximately $308.8 million in guaranteed senior certificates and about $34.3 million in non-guaranteed subordinate certificates, with the subordinate certificates auctioned on October 24, 2025 [2]. - The expected settlement date for the transaction is October 30, 2025 [2]. Group 2: Underlying Collateral - The collateral backing the certificates consists of 1,985 seasoned loans, including fixed, adjustable, and step-rate loans, with none being more than 150 days delinquent as of the cut-off date [3]. - The loans include both modified loans aimed at assisting borrowers at risk of foreclosure and loans that were never modified [3]. Group 3: Advisory and Management - Advisors for this transaction include Citigroup Global Markets Inc. and Nomura Securities International, Inc. as co-lead managers and joint bookrunners, along with several co-managers [4]. Group 4: Freddie Mac's Strategy - Freddie Mac's seasoned loan offerings aim to reduce less-liquid assets in its mortgage-related investments portfolio through economically sensible transactions, including the sale of Non-Performing Loans (NPLs) and securitizations of re-performing loans (RPLs) [5]. - Since 2011, Freddie Mac has sold approximately $10.7 billion of NPLs and securitized about $81.3 billion of RPLs, which includes $30.4 billion of fully guaranteed MBS, $37.6 billion through the Seasoned Credit Risk Transfer (SCRT) program, and $13.3 billion through the SLST program [5].

Core Viewpoint - Solventum Corporation announced a secondary offering of 8,800,000 shares of its common stock, all being sold by 3M Company, with Solventum not receiving any proceeds from the offering [1]. Group 1: Offering Details - The offering consists of 8,800,000 shares of common stock with a par value of $0.01 per share [1]. - Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as underwriters for the offering [2]. - The shares are being offered under the Company's shelf registration statement on Form S-3, effective as of August 13, 2025 [3]. Group 2: Regulatory Information - The offering will be conducted only through a preliminary prospectus supplement filed with the SEC and the accompanying prospectus [3]. - Interested parties can obtain the preliminary prospectus supplement and accompanying prospectus for free via the SEC's EDGAR database or by contacting the underwriters directly [3]. Group 3: Company Background - Solventum aims to enable better healthcare through innovative solutions at the intersection of health, material, and data science [7].

Company Overview - Highwoods Properties, Inc. is a publicly-traded real estate investment trust (REIT) focused on owning, developing, acquiring, leasing, and managing properties in major business districts across several cities including Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa [4] Financial Update - Highwoods Properties has recast a $200 million unsecured bank term loan, extending its maturity from May 2026 to January 2029, with an option to extend for an additional two years if no defaults occur [1] - The interest rate on the new term loan is set at SOFR plus 95 basis points, with potential adjustments of up to 2.5 basis points based on the achievement of specific sustainability goals related to greenhouse gas emissions reduction [2] Loan Arrangement Details - The new term loan was arranged by several financial institutions, including BofA Securities, Wells Fargo Securities, and PNC Capital Markets, with Bank of America acting as the Administrative Agent [3]

Core Viewpoint - Verisk Analytics, Inc. is offering $750 million of 4.500% Senior Notes due 2030 and $750 million of 5.125% Senior Notes due 2036 to finance the acquisition of AccuLynx for approximately $2.35 billion [1][2]. Group 1: Offering Details - The offering consists of two sets of Senior Notes: $750 million of 4.500% Senior Notes due 2030 and $750 million of 5.125% Senior Notes due 2036 [1]. - The closing of the offering is expected on August 21, 2025, pending customary closing conditions [1]. - Goldman Sachs & Co. LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with borrowings from a senior unsecured three-year delayed draw term loan facility and cash on hand, will be used to finance the acquisition of AccuLynx [2]. - The total purchase price for the acquisition is approximately $2.35 billion [2]. Group 3: Company Overview - Verisk is a leading global data analytics and technology provider, primarily serving the insurance industry [6]. - The company focuses on enhancing operational efficiency, improving underwriting and claims outcomes, and addressing global risks such as climate change and sustainability [6]. - Verisk operates in over 20 countries and is recognized for fostering an inclusive workplace culture [6].

Core Viewpoint - MPLX LP has successfully priced $4.5 billion in unsecured senior notes to fund acquisitions and general partnership purposes [1][2]. Group 1: Offering Details - The offering consists of four tranches: $1.25 billion of 4.800% senior notes due 2031, $750 million of 5.000% senior notes due 2033, $1.5 billion of 5.400% senior notes due 2035, and $1.0 billion of 6.200% senior notes due 2055 [1]. - The closing of the offering is expected on August 11, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - A portion of the net proceeds will fund the acquisition of Northwind Delaware Holdings LLC and cover related fees and expenses [2]. - The remaining proceeds will be used for general partnership purposes, including capital expenditures and working capital [2]. Group 3: Company Overview - MPLX is a diversified, large-cap master limited partnership that operates midstream energy infrastructure and logistics assets, including pipelines, terminals, and storage facilities [6].

WASHINGTON, Aug. 5, 2025 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) today announced the results of its twenty-seventh non-performing loan sale transaction. The deal, announced on July 8, 2025, included the sale of 1,304 deeply delinquent loans totaling $285 million in unpaid principal balance (UPB), offered in two pools. The winning bidder for Pool 1 was Residential Credit Opportunities Trust X-C, and for Pool 2 was RCF II Loan Acquisition, LP. The transaction is expected to close on September 19, 2025. The d ...